Derived from a peptide, no longer one
Dihexa came out of work on angiotensin IV, a fragment of the angiotensin system with activity in the brain that is separate from the blood pressure role the system is known for. Researchers modified that starting point substantially, aiming for something that would survive metabolism and reach the brain.
What emerged is best described as a small molecule with peptide ancestry. Calling it a peptide is convenient shorthand and it is not accurate, which matters when you are looking for the right literature.
Ask what is dihexa and the answer has to open with a correction, because the ancestry is the part people remember. What was carried over from the parent fragment is the piece the research is aimed at; what was added is the chemistry that lets the molecule last long enough to study, and the addition is substantial enough that the peptide description stops fitting.
Hepatocyte growth factor, in the brain
The proposed mechanism involves hepatocyte growth factor and its receptor c-Met. Despite the name, that pair is not confined to the liver: it has documented roles in the nervous system, including in synapse formation.
Research has looked at synaptic connectivity and at behavioural measures in animal models of cognitive impairment. The work comes largely from the group that developed the compound, and independent replication is limited.
Working through a growth factor system rather than a surface receptor changes how the evidence reads. A signal that shapes how connections form is measured in structures and over days rather than in a binding curve, so the endpoints in this literature are things like connectivity in tissue and performance on a task, softer measures than a receptor assay, and correspondingly easier to over-read.
| Type | Small molecule with peptide ancestry |
| Derived from | Angiotensin IV |
| Proposed target | Hepatocyte growth factor and c-Met |
| Research focus | Synaptic connectivity, animal cognition models |
| Format | Capsules |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Animal work, largely one group |
| Category | Research use only |
Composition and handling detail. The rows stop at the material.
Why it survives the oral route
The modifications that made dihexa metabolically stable are also what make an oral format worth considering. A peptide of similar size would not survive the digestive tract; this molecule was designed not to be one.
Very little in this catalogue qualifies. A compound earns a place in the capsule list one of two ways: it resists degradation unusually well, or its target sits inside the gut itself. Dihexa belongs to the first group.
That stability is a property of the finished molecule rather than of its ancestry, which is the practical reason the capsule format applies here and to almost nothing else in the catalogue; the primary work sits behind the record on PubMed. The chemistry does not change what a batch has to prove, either: the certificate of analysis establishes identity and purity here exactly as it does for a sequence.
A modified molecule and what a batch can prove
Derived from a peptide, then changed enough to stop being one, dihexa is a fair test of reading labels carefully. What can still be stated cleanly is identity and purity per batch, released for research use only, the category that governs how it may be handled.
Two questions are worth keeping apart on a page like this one. How strong the evidence is depends on who has repeated the work and in which models; what is in the capsule depends on the quality standard behind release and the batch record that goes with it. A thin literature and a well-documented batch can coexist, and here they do.
Dihexa in the catalogue
Held to a 99% HPLC floor, with the release document tied to the lot number.
Where Dihexa fits in
Adjacent topics that make this one easier to place.
About Dihexa
Short answers to questions we hear repeatedly.